Selective inhibitor of transforming growth factor-β type I receptor (ALK5) (IC50 values are 0.018 and 0.093 μM for ALK5 binding and for TGF-β cellular assay respectively). Inhibits esopheageal squamous cell carcinoma (ESCC)-induced neoangiogenesis. Orally active.